Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-038959
Filing Date
2020-08-10
Accepted
2020-08-10 16:31:46
Documents
72
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sbph-10q_20200630.htm   iXBRL 10-Q 2237015
2 EX-31.1 sbph-ex311_8.htm EX-31.1 23513
3 EX-31.2 sbph-ex312_7.htm EX-31.2 22993
4 EX-32.1 sbph-ex321_9.htm EX-32.1 16090
  Complete submission text file 0001564590-20-038959.txt   8805299

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sbph-20200630.xsd EX-101.SCH 53513
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sbph-20200630_cal.xml EX-101.CAL 47427
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sbph-20200630_def.xml EX-101.DEF 199733
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbph-20200630_lab.xml EX-101.LAB 442424
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbph-20200630_pre.xml EX-101.PRE 356843
10 EXTRACTED XBRL INSTANCE DOCUMENT sbph-10q_20200630_htm.xml XML 1805758
Mailing Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748
Business Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748 508-473-5993 X119
Spring Bank Pharmaceuticals, Inc. (Filer) CIK: 0001566373 (see all company filings)

EIN.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37718 | Film No.: 201089841
SIC: 2834 Pharmaceutical Preparations